Archives

  • 2019-07
  • 2019-08
  • 2019-09
  • 2019-10
  • 2019-11
  • 2020-03
  • 2020-07
  • 2020-08
  • 2021-03
  • br A meta analysis of data taken from

    2019-09-16


    A meta-analysis of data taken from the Cancer Genome Atlas (TCGA) cohort (Project Id: TCGA-Breast Cancer) (n = 780 patients) (https:// portal.gdc.cancer.gov/projects/TCGA-BC) demonstrated that over five
    years, patients with clinically-diagnosed Puromycin receptor negative breast cancer had similar survival rates regardless of CYP24A1 ex-pression. However, patients with estrogen receptor positive breast cancer with higher-than-median CYP24A1 levels had significantly better survival rates over 5 years than patients with low levels of CYP24A1 (Fig. 4). Another meta-analysis of vitamin D supplementation in breast cancer patients that considered estrogen receptor positive/ negative and progesterone receptor positive/negative subtypes found that although vitamin D supplementation was associated with de-creased recurrence rates in patients with estrogen receptor positive cancer, there was no correlation between vitamin D supplementation and hazard ratios in patients with estrogen receptor negative cancer [2]. These results were maintained regardless of progesterone receptor status, suggesting that estrogen receptor status is a better outcome marker of vitamin D supplementation efficacy than progesterone re-ceptor. Taken together, these results suggest that estrogen receptor expression could be of clinical importance in the efficacy of vitamin D supplementation in breast cancer patients Fig. 5.
    7. Perspectives
    Although connections between improved breast cancer prognoses and high vitamin D serum levels have been well-established, there is no consensus on the efficacy of vitamin D supplementation in the treat-ment of breast cancer. Studies examining breast cancer prognosis and vitamin D serum levels could be improved by considering the breast cancer molecular subtypes, particularly the estrogen receptor status, of the patients involved. 24R,25(OH)2D3, an understudied vitamin D3 metabolite, may have potential as a less-calcemic vitamin D3 metabo-lite with tumor modulating properties. Further research is needed to understand the connections between estrogen receptor status and the anti-tumorigenicity of vitamin D supplements, and the parallels be-tween membrane mediated estrogen signaling through ERα36 and 24R,25(OH)2D3 may provide insight into this connection.
    Acknowledgements
    Services in support of the research project were provided by the VCU Massey Cancer Mouse Models Core, supported, in part, with funding from NIH-NCI Cancer Center Support Grant P30 CA016059.
    Appendix A. Supplementary data
    References
    [24] L. Hunakova, O. Sedlakova, D. Cholujova, P. Gronesova, J. Duraj, J. Sedlak, Modulation of markers associated with aggressive phenotype in MDA-MB-231 breast carcinoma cells by sulforaphane, Neoplasma 56 (2009) 548–556. [25] J. Hurst-Kennedy, B.D. Boyan, Z. Schwartz, Lysophosphatidic acid signaling pro-motes proliferation, differentiation, and cell survival in rat growth plate chon-drocytes, Biochim. Biophys. Acta. 1793 (2009) 836–846.
    [41] M.T. Mizwicki, D. Keidel, C.M. Bula, J.E. Bishop, L.P. Zanello, J.-M. Wurtz, et al., Identification of an alternative ligand-binding pocket in the nuclear vitamin D re-ceptor and its functional importance in 1α,25(OH)2-vitamin D3 signaling, Proc.
    [52] B.D. Boyan, D.D. Dean, V.L. Sylvia, Z. Schwartz, Steroid hormone action in mus-culoskeletal cells involves membrane receptor and nuclear receptor mechanisms, Connect. Tissue Res. (2003).
    [85] A. Jara, C. Chacon, A.J. Felsenfeld, How dietary phosphate, renal failure and cal-citriol administration affect the serum calcium-phosphate relationship in the rat, Nephrol. Dial. Transplant. 17 (2002) 765–771.
    [95] D. Richter, S. Abarzua, M. Chrobak, T. Vrekoussis, T. Weissenbacher, C. Kuhn, et al., Effects of phytoestrogen extracts isolated from pumpkin seeds on estradiol pro-duction and ER/PR expression in breast cancer and trophoblast tumor cells, Nutr. Cancer. 65 (2013) 739–745.